a cure for hep c, aids, the flu and dengue..., page-116

I have jumped in with some BITOs, the story is just too compelling. I have been reading the Southern Cross Equities 2009 report and it gives paints a very bright picture, here are a few quotes:

"In March 2006 Biotron was able to announce that a number of its compounds had been tested against strains of influenza and that one compound had shown good activity against the H5N1 (Bird Flu) strain. What this announcement demonstrated was the power of the Biotron library.Not only did the company have a potential anti-influenza candidate, but it was able to quickly create an assay to do high-throughput screening to look for further drug candidates."

"When Biotron was formed in 2000 it was a biotech 'incubation' company, designed to work on a number of very early stage projects then emerging from the ANU's John Curtin School of Medical Research."

"C-Test is designed to detect cancers at their early stages of development. The thinking is that cancers have a different glycolipid expression pattern in blood sera to ordinary sera. Scientists have developed techniques for extracting certain carbohydrates from the blood and then analysing the expression profile of the carbohydrates using proprietary algorithms. The technology has been trialled using blood sera from patients with various kinds of cancers."

"GeneTrans is a test that can help predict the effect of new drugs. The technology is based on MRP2, a so-called 'drug transport' protein whose function, as the name suggests, is to move drugs across the walls of cells.
Scientists have created a cell line that expresses MRP2, and the rate at which these cells die when exposed to drug candidates can provide a good indication as to whether or not the drug is toxic to cells."

"Muscion is a project focused on small molecule drugs that target calcium channels called 'ryanodine receptors'. The thinking is that these drugs, by releasing calcium inside heart cells, can induce heart muscle to contract. This could lead to a new-generation drug to treat heart failure."

"Biotron has retained ownership of C-Test although that project is currently on hold while the company focuses on BIT225. As for the other two projects, under a December 2006 deal with ANU Biotron received $440,000 for relinquishing rights to the possible future intellectual property from the projects, but will receive a royalty from commercialisation should it occur. The development of GeneTrans and Muscion will not require any funding by Biotron."

A cancer screener, royalties for a drug toxicity indicator and a heart medicine on top of having potentially one of the worlds best anti-virals.... I'm glad I got a bit.